Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
ABG Lab is a premier biotechnology company based in the United States that specializes in the development of advanced aesthetic and anti-aging solutions. The company is renowned for its proprietary peptide technologies, most notably the Wharton’s Jelly Peptide (P199), which focuses on the activation of endogenous stem cells to promote tissue regeneration. Their product portfolio includes flagship brands such as Meso-Wharton P199, Meso-Xanthin F199, Meso-Sculpt C71, and Meso-Eye C71, which target a wide range of dermatological concerns from deep wrinkles to localized fat deposits. By integrating cutting-edge cellular biology with clinical aesthetics, ABG Lab provides non-surgical rejuvenation treatments that leverage epigenetic regulation. The company maintains a global presence, supplying clinical-grade products to aesthetic physicians and dermatologists worldwide.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on ABG Lab.